Group items tagged

Folding Lightweight Wheelchairs For indoor wheelchair safety the folding power wheelchair models that are lightweight have front casters which turn easily, making them ideal for use in small apartments. Having the casters in front makes this a dangerous chair to use outdoors as the front wheels can turn sharply if encountering a crack in the sidewalk, incline, or rocks.Wheelchair india is manufacturer, supplier, distributor and dealer of Karma KP 10-2 Power Wheelchair for disabled and handicapped in india. They usually have one or two removable batteries and have a similar appearance as the manual wheelchair. They can be controlled with a joystick or a sip and puff method. Lightweight Power Assisted Wheelchairs These chairs can be propelled in a similar manner as the manual wheelchair or use a battery. You may want this type if you want to keep fit and get some exercise but need some power when going up an incline or when traveling a distance. They are smaller and lighter weight than the folding wheelchair and have smaller batteries and motors. Dual Purpose Power Wheelchairs These chairs generally are good for either indoor or outdoor use. You need to have larger wheels in front for outdoors as this is a safety feature. It is better to have six wheels for stability when traveling outdoors. These indoor/outdoor power chairs compromise wheelchair safety and perform poorly when you do not have enough room to turn indoors and you need to travel over rough ground and uneven surfaces. Their optimum performance indoors is when you have wider doors and hallways in assisted living facilities, nursing homes, or homes/apartments. Ideal outdoor surfaces in urban and suburban areas would include sidewalks and paved areas. Outdoor Power Wheelchairs These chairs weigh as much as 400-500 pounds, add the weight of the user up to 250 pounds and the total weight is approximately 650 pounds. They are very efficient outdoors with their rear wheels they can sa

A surrogate mother often faces criticism and judgment from others for the choice she have made. However, those are less problematic when compare to the risks that she takes for her own family, friends and spouse. These risks can be daunting and cause challenges she might not have considered before getting involved. These risks can be anything from medical and health concerns to finances and job security and often family and personal risks as well. Medical risk is a huge factor, when a woman becomes a surrogate often times, she and the donors would have to undergo intense examination. These exams range from blood, health tests to the initial process of the implanting of the eggs from the donor. In the beginning the clinic will bring her and the egg donor together to begin a lengthy process of sequencing ovulation cycles. The clinic would put the surrogate mother on birth control and steroids, such as Luprin. These medications are meant to get both the surrogate mother and the donor's cycles on the same schedule. This is crucial because the surrogates' uterus needs to be ready for the embryos. Just having to deal with the pain of insemination and testing can be unbearable, not to mention the unpleasant side effects from all the medication and actual insemination process. However, that is just part of it. The surrogates are also faced with depression, sleep disturbance, guilt and the difficulty to remain unattached. These factors alone cause many surrogates to face the fact that they are walking a long road that not many others might have the strength to do. Many clinics offer support groups and counseling. Aside from medical and emotional risks, there might also be legality issues with the laws of the state they reside in. What kind of laws protect the surrogate, what rights does she have to things such as privacy? And there are also finances to consider. Generally, surrogate mothers are responsible for all insurance costs. As a surrogate you should be financially

Use of cholesterol lowering drugs may significantly cut cardiovascular risks, but its long term use can raise the risk of developing cataracts by 27 percent, researchers have found.

Surrogacy is perhaps one of the most selfless acts that a woman can bestow upon a couple in need of a child. Surrogacy, however, can come with both physical and physiological risks that may or may not be easy to recover from. Understanding what the psychological risks of surrogate motherhood can make the transition from carrying a child to relinquishing that child easier. The psychological risks of surrogate motherhood may be a heavier burden to carry, but pre-screening and on-going counseling both before and after the event can help surrogate mothers adjust. There are four areas that are of particular interest in the psychological aspect of surrogacy: contact (bonds), control, closure and ethics. Surrogate mothers form relationships with the couples they surrogate for and that bond may perhaps be even stronger than the bond they may feel for the child they are carrying. They see and talk to their couples regularly and become used to the caring bestowed upon them from their couples. These bonds are strengthened by the routine prenatal visits, maternity clothes shopping, calls to see how they are feeling or if they need anything for comfort. These routine events cause them to become almost dependent on their couples and some surrogates report even becoming depressed after the birth not because of having to relinquish the child, but because they no longer have a reason for contact with their couples. Another one of the psychological risks of surrogate motherhood is that of closure. Often, this can go hand in hand with every contact or bonding issues. The routines and relationships developed between the surrogate, couples and medical staff that often make the transition from pregnancy and surrogacy to the birth and farewell stage that makes it difficult. Not only does the surrogate have to deal with the loss of a child, per se, but also the loss of those unique and caring relationships and routines that they have grown used to over the previous nine months. And fina

A woman must fully comprehend what it means to be a surrogate mother. She needs to know what her body will go through, what the couple she is working for will expect of her while she is carrying their child and what the risks are in all of this. A woman may enjoy the idea of being pregnant and carrying a child but she must think of the risks of surrogate motherhood before she embarks on such a long journey. One of the risks involved in surrogate motherhood is the pregnancy itself. A natural pregnancy is dangerous; let alone an artificial one. Complications happen that can't always be avoided. It is simple fate that may lead you to miscarry, or acquire health problems from the pregnancy. Though using a surrogate motherhood agency is the safest way to go, no one can promise you that there will be no complications. If and when you are pregnant with someone else's child, you are responsible for taking care of it while in your womb. What you eat, drink and take into your body will affect the child. Not everyone has the self discipline to take their vitamins every day or not smoke a cigarette. If something happens and the child is born with a problem that could possibly be because of you and what you did to your body during pregnancy, then you will be investigated. It may not have been your fault, but if the possibility exists then the agency has to look into it. When you get into surrogate motherhood, you become business partners with the parents of the child for the duration of the pregnancy. There is no backing out. If the couple that you chose turns out to be mean or irresponsible, you are stuck with them until the baby is born. This is especially dangerous if you are not using a surrogate agency. If the couple skips town, you won't be taken care of and will be stuck with a baby to raise. What happens if the child is born with some kind of deformity or disease? The parents may not want the child. So then, is it you that takes care of it? Is it put up for a

New research shows that lifelong excess weight almost doubles a woman's risk of developing womb cancer. The findings of the study were published in 'BMC Medicine'. The study from the University of Bristol is one of the first to find that for every fiver extra BMI units, a woman's risk of womb (endometrial) cancer is almost doubled (an increase of 88 per cent). This is higher than most previous studies have suggested and reflects lifelong weight status rather than a snapshot in time like most other studies. Five BMI units is the difference between the overweight category and the obese category, or of a 5'5 adult woman being two stones heavier. The international study looked at genetic samples from around 120,000 women from Australia, Belgium, Germany, Poland, Sweden, the UK, and the USA of which around 13,000 had womb cancer. This large statistical analysis is one of the first studies of its kind to look at the effect of lifelong greater BMI on womb cancer risk.

The Joint Committee on Vaccination and Immunisation (JCVI) has advised booster vaccination to be offered this autumn (2023) for those at higher risk of severe Covid-19 in its interim advice to government on the coronavirus (COVID-19) vaccination programme for 2023. The JCVI also advised that for a smaller group of people, such as those who are older and those who are immunosuppressed, an extra booster vaccine dose in the spring should also be planned for. Professor Wei Shen Lim, Chair of Covid-19 vaccination on the JCVI, said: "The Covid-19 vaccination programme continues to reduce severe disease across the population, while helping to protect the NHS. That is why we have advised planning for further booster vaccines for persons at higher risk of serious illness through an autumn booster programme later this year. We will very shortly also provide final advice on a spring booster programme for those at greatest risk."

The widely-held concept that levels of "good" cholesterol in the blood can indicate heart disease risk is not equally true for Blacks and whites, and the measure itself may be of less value than previously thought, according to a U.S. study published on Monday (November 21). Various types of cholesterol are thought to have either healthy or unhealthy effects. Low levels of so-called "good" high-density lipoprotein (HDL) cholesterol were linked with higher odds for developing cardiac problems in the long-term study - but only in white participants, the study published in the Journal of the American College of Cardiology found. In contradiction to what has generally been assumed, low HDL levels did not confer any higher risk of heart disease in Black people, researchers said. Among white people, however, those with HDL levels below 40 milligrams per deciliter had a 22% higher risk for coronary heart disease compared with those whose HDL levels were higher. High HDL levels (above 60 mg/dL), which are thought to be protective, were not linked with lower coronary heart disease risks in either race, researchers found.

The World Health Organization said on Sunday (May 29) that monkey pox constitutes a "moderate risk" to overall public health at global level after cases were reported in countries where the disease is not typically found. "The public health risk could become high if this virus exploits the opportunity to establish itself as a human pathogen and spreads to groups at higher risk of severe disease such as young children and immunosuppressed persons," WHO said. As of May 26, a total of 257 confirmed cases and 120 suspected cases have been reported from 23 member states that are not endemic for the virus, the health agency said in a statement. There has been no reported fatalities so far. WHO also said that the sudden appearance of monkeypox at once in several non-endemic countries suggests undetected transmission for some time and recent amplifying events. The agency added that it expects more cases to be reported as surveillance in endemic and non-endemic countries expands. Monkeypox is an infectious disease that is usually mild, and is endemic in parts of west and central Africa. It is spread by close contact, so it can be relatively easily contained through measures such as self-isolation and hygiene.

Recently launched generic version of Apixaban by Teva UK is said to bring savings to the NHS drug bill while making sure patients get the medicine they need. The generic apixaban is available for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA) and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Previously there was only a 'branded' product available, but Castleford-based Teva UK succeeded in invalidating the apixaban patent and SPC (supplementary protection certificate) in the UK High Court and so is now able to launch its own 'generic' version - which will bring savings for the NHS while making sure patients get the medicine they need. "We've always said that we stand up for the patient", said Kim Innes, General Manager of Teva UK and Ireland. "The launch of generic apixaban emphasises Teva's commitment to doing the right thing by putting patients at the heart of everything we do by giving them and the NHS access to affordable treatments." Apixaban is an anticoagulant which directly inhibits factor X (factor Xa), inhibiting thrombin formation and the development of thrombi (blood clots). For at-risk patients, such as those with, or at risk for DVT, or NVAF, the risk of stroke related to blood clots forming in the body and traveling to the brain is a serious concern. Each year, DVT affects around 1 person in every 1,000 in the UK and if left untreated, about 1 in 10 people with a DVT will develop a PE.

UK regulator has approved a second oral antiviral for early treatment of Covid-19 in high-risk adults, after molnupiravir. The Medicines and Healthcare products Regulatory Agency (MHRA) gave its nod for a new treatment called Paxlovid (PF-07321332 and ritonavir), after finding it safe and effective at reducing the risk of hospitalisation and death in people diagnosed with mild Covid-19 infection. Developed by Pfizer, Paxlovid prevents the multiplying of virus, helping the body to overcome the infection. A clinical trial for the treatment in high risk individuals revealed that a five-days course of Paxlovid reduces the risk of hospitalisation and death by 89 per cent. It further revealed that Paxlovid is most effective when taken in the early stage of infection. Dr June Raine, MHRA chief executive, said: "We now have a further antiviral medicine for the treatment of Covid-19 that can be taken by mouth rather than administered intravenously. This means it can be administered outside a hospital setting, before Covid-19 has progressed to a severe stage."

The National Institute for Health and Care Excellence (NICE) has recommended icosapent ethyl also called Vazkepa manufactured by Amarin for adults who have cardiovascular disease with controlled LDL-C levels taking a statin. It's final draft guidance is expected to be available on the July 20. Nearly half a million people are expected to benefit from the first licensed treatment shown to reduce the risk of heart attacks and strokes in people with controlled low-density lipoprotein cholesterol (LDL-C - sometimes called "bad" cholesterol) who are taking a statin and who have raised levels of triglycerides. NICE said: "Clinical trial evidence suggests that for people with raised triglycerides who have LDL-C levels controlled by statins, and who have cardiovascular disease, icosapent ethyl reduces their risk of cardiovascular events by over a quarter compared with placebo. Helen Knight, interim director of medicines evaluation at NICE, said: "Icosapent ethyl is the first licensed treatment of its kind for people who are at risk of heart attacks and strokes despite well controlled LDL cholesterol because they have raised blood fats. And although lifestyle changes, including diet and exercise, can help to reduce their risk, these may not work for everyone.

Ninety-six per cent of community pharmacists surveyed in the Royal Pharmaceutical Society (RPS) Workforce Wellbeing survey said they were at 'risk of burnout'. A higher number of respondents working in community pharmacy (20%) reported not being offered breaks compared to all other sectors (8%) and were more likely to experience verbal or physical abuse from patients and the public (69% vs an average 44%). The annual Workforce Wellbeing survey also revealed that 88 per cent of pharmacists surveyed are at high risk of burnout due to winter pressure. Therefore, RPS is calling for workforce planning for pharmacy to address skill mix and staffing levels so that workloads can be effectively managed. Top factors causing poor mental health and wellbeing revealed by the survey include inadequate staffing (70%), lack of work/life balance (53%), lack of protected learning time (48%) and lack of colleague/senior support (47%). This is the fourth survey RPS has run in partnership with the charity Pharmacist Support on the state of mental health and wellbeing in pharmacy. The findings demonstrate continued pressure on pharmacists and trainees across the workforce, especially in community pharmacy where 96% of those surveyed said they were at risk of burnout.

The Medicine and Healthcare products Regulatory Agency (MHRA) has cautioned men on valproate to talk to their healthcare professional about their treatment, if they want to start a family in the next year. The warning came after a new study, commissioned by the European Medicines Agency, suggested that children fathered by men who took the anti-seizure medicine in the three months prior to conception may be at higher risk of developing neurodevelopmental disorders. Around five in 100 children born to fathers treated with valproate around conception were diagnosed with a neurodevelopmental disorder, compared to three in 100 children whose fathers were taking other antiseizure medicines (lamotrigine or levetiracetam). However, the risk is believed to be much smaller than the risk associated with valproate in pregnancy.

As per a new study, Inflammatory bowel disease can result into heart disease.

Being overweight as a teenager carries a greater risk of being an overweight adult, along with an increased risk of dying of heart disease. But overweight adolescents who slim down in middle age may lower their risk, a new study shows.

The Medicines and Healthcare products Regulatory Agency (MHRA) has advised the public to exercise caution when buying anti-choking devices online, ensuring these products are purchased from reputable sellers. As estimated by the regulator, more than 10,000 counterfeit or unbranded anti-choking devices have been purchased by the public within the last two years through listings on online marketplaces such as Amazon and eBay, as well as drop-shipping websites. People are cautioned that the use of such products poses a substantial risk of failure in clearing blockages and could exacerbate the situation by pushing obstructions further down into the airway passage. Dr Alison Cave, MHRA Chief Safety Officer, said: "Buying anti-choking devices that do not have a valid UKCA or CE mark increases the risk of receiving a product which does not include appropriate instructions and is either fake or does not meet the UK's regulatory requirements. "These products do not meet our strict quality standards and may put your health and safety at significant risk by failing to resolve or even worsening choking incidents."